» Articles » PMID: 16864166

SweDCIS: Radiotherapy After Sector Resection for Ductal Carcinoma in Situ of the Breast. Results of a Randomised Trial in a Population Offered Mammography Screening

Overview
Journal Acta Oncol
Specialty Oncology
Date 2006 Jul 26
PMID 16864166
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the effect of postoperative radiotherapy (RT) after breast sector resection for ductal carcinoma in situ (DCIS). The study protocol stipulated radical surgery but microscopically clear margins were not mandatory. We randomised 1,046 operated women to postoperative RT or control between 1987 and 1999. The primary endpoint was ipsilateral local recurrence. Secondary endpoints were contralateral breast cancer, distant metastasis and death. After a median follow-up of 5.2 years (range 0.1-13.8) there were 44 recurrences in the RT group corresponding to a cumulative incidence of 0.07 (95% confidence interval (CI) 0.05-0.10). In the control group there were 117 recurrences giving a cumulative incidence of 0.22 (95% CI 0.18-0.26) giving an overall hazard ratio of 0.33 (95% CI 0.24-0.47, p < 0.0001). Twenty two percent of the patients had microscopically unknown or involved margins. We found no evidence for different effects of RT on the relative risk of invasive or in situ recurrence. Secondary endpoints did not differ. Women undergoing sector resection for DCIS under conditions of population based screening mammography benefit from postoperative RT to the breast. Seven patients needed RT-treatment to prevent one recurrence.

Citing Articles

Management of Ductal Carcinoma In Situ: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.

Brackstone M, Durocher-Allen L, Califaretti N, Eisen A, Knowles S, Salim A Curr Oncol. 2024; 31(12):7738-7753.

PMID: 39727692 PMC: 11675061. DOI: 10.3390/curroncol31120569.


Risk of developing subsequent primary lung cancer after receiving radiation for breast cancer.

Wong L, Kapula N, He H, Guenthart B, Vitzthum L, Horst K JTCVS Open. 2024; 16:919-928.

PMID: 38204675 PMC: 10775166. DOI: 10.1016/j.xjon.2023.10.031.


Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma .

Dabbs D, Mittal K, Heineman S, Whitworth P, Shah C, Savala J Front Oncol. 2023; 13:1069059.

PMID: 37274253 PMC: 10236475. DOI: 10.3389/fonc.2023.1069059.


Locoregional Control Benefit of a Tumor Bed Boost for Ductal Carcinoma In Situ.

Dreyfuss A, Max D, Flynn J, Zhang Z, Gillespie E, Xu A Adv Radiat Oncol. 2023; 8(5):101254.

PMID: 37250283 PMC: 10220256. DOI: 10.1016/j.adro.2023.101254.


The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment.

Nash A, Hwang E Ann Surg Oncol. 2023; 30(6):3206-3214.

PMID: 37024766 DOI: 10.1245/s10434-023-13370-1.